Ruxolitinib for the Treatment of Severe Alopecia Areata

September 2018 in “ Journal of the American Academy of Dermatology ”

Lucy Liu, Brett King

ruxolitinib JAK1/2 inhibitor alopecia areata JAK inhibitors

TLDR Ruxolitinib can help regrow hair in severe alopecia areata.

In a study involving 8 patients with severe alopecia areata (AA), ruxolitinib, a JAK1/2 inhibitor, was shown to induce hair regrowth at a lower dose than previously reported. This finding builds on earlier research indicating the efficacy of JAK inhibitors in treating AA, highlighting ruxolitinib as a promising treatment option for severe cases.

View this study on jaad.org →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring

25 citations, March 2017 in “International Journal of Dermatology”

Ruxolitinib effectively and safely regrows hair in alopecia patients.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations, November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations, September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations, September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations, August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Related Research

9 / 9 results

research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata

August 2023 in “International journal of research in dermatology”

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review

2 citations, June 2023 in “Indian journal of dermatology, venereology, and leprology”

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations, February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature

17 citations, January 2019 in “Journal of cutaneous medicine and surgery”

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

research Oral Janus Kinase Inhibitors for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis

January 2019 in “프로그램북(구 초록집)”

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

research Ruxolitinib for the Treatment of Severe Alopecia Areata

37 citations, September 2018 in “Journal of the American Academy of Dermatology”

Ruxolitinib can help regrow hair in severe alopecia areata.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations, July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.

research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents

28 citations, December 2017 in “Journal of Investigative Dermatology Symposium Proceedings”

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

research Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature

40 citations, December 2016 in “Journal of Dermatological Treatment”

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.